文献速递淋巴瘤

维泊妥珠单抗联合化学免疫治疗初治弥漫大B细胞淋巴瘤的成本效益

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

基于POLARIX研究,构建Markov模型评估美国初治弥漫大B细胞淋巴瘤(DLBCL)成人(平均年龄65岁)使用维泊妥珠单抗联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松(pola-R-CHP)相比标准R-CHOP的成本效益,支付意愿阈值为每质量调整生命年15万美元。假设pola-R-CHP的5年无进展生存率为69.6%、R-CHOP为62.7%时,pola-R-CHP具有成本效益(增量成本效益比为84,308美元/QALY)。若pola-R-CHP的5年无进展生存率降至66.1%或更低,则不再具有成本效益。

要点

  • 在5年无进展生存率69.6% vs 62.7%的假设下,pola-R-CHP的增量成本效益比为84,308美元/QALY,低于15万美元/QALY的支付意愿阈值。
  • 若pola-R-CHP的5年无进展生存率降至66.1%或更低,则不再具有成本效益。
  • 单因素敏感性分析显示,在15万美元/QALY的支付意愿下,pola-R-CHP的成本高达276,312美元时仍具有成本效益。

核心结论

  • 若无进展生存的绝对获益随时间维持,在15万美元/QALY的支付意愿下,pola-R-CHP相比R-CHOP具有成本效益,但其成本效益高度依赖于长期结局和嵌合抗原受体T细胞治疗的成本。

研究设计与样本

  • 研究构建Markov模型(终身 horizon),模拟美国初治DLBCL成人假设队列(平均年龄65岁),评估pola-R-CHP与R-CHOP的成本效益。
  • 进展率和总生存率从POLARIX研究估计。

主要发现

  • POLARIX研究报告pola-R-CHP相比R-CHOP的2年无进展生存率提高6.5%,总生存或安全性无差异。
  • 假设pola-R-CHP的5年无进展生存率为69.6%、R-CHOP为62.7%,pola-R-CHP在15万美元/QALY的支付意愿下具有成本效益,增量成本效益比为84,308美元/QALY。
  • 若pola-R-CHP的5年无进展生存率为66.1%或更低,则不再具有成本效益。
  • 单因素敏感性分析显示,在15万美元/QALY的支付意愿下,pola-R-CHP的成本高达276,312美元时仍具有成本效益。
  • 在10,000次蒙特卡洛迭代中,56.6%的情况下pola-R-CHP具有成本效益。

关键数值与推荐

  • 支付意愿阈值设定为15万美元/QALY。
  • 增量成本效益比为84,308美元/QALY(pola-R-CHP vs R-CHOP,假设5年无进展生存率69.6% vs 62.7%)。
  • pola-R-CHP具有成本效益的最高成本为276,312美元(单因素敏感性分析,支付意愿15万美元/QALY)。

临床怎么用

  • 常规使用pola-R-CHP将显著增加医疗支出。
  • 降价或识别最大获益亚组可改善成本效益。

局限性

  • 成本效益高度依赖于长期结局和嵌合抗原受体T细胞治疗的成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with treatment-naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study (A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone [R-CHP] Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [R-CHOP] in Participants With Diffuse Large B-Cell Lymphoma) reported a 6.5% improvement in the 2-year progression-free survival (PFS), with no difference in overall survival (OS) or safety using polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) compared with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). We evaluated the cost-effectiveness of pola-R-CHP for DLBCL. We modeled a hypothetical cohort of US adults (mean age, 65 years) with treatment-naive DLBCL by developing a Markov model (lifetime horizon) to model the cost-effectiveness of pola-R-CHP and R-CHOP using a range of plausible long-term outcomes. Progression rates and OS were estimated from POLARIX. Outcome measures were reported in incremental cost-effectiveness ratios, with a willingness-to-pay (WTP) threshold of $150 000 per quality-adjusted life-year (QALY). Assuming a 5-year PFS of 69.6% with pola-R-CHP and 62.7% with R-CHOP, pola-R-CHP was cost-effective at a WTP of $150 000 (incremental cost-effectiveness ratio, $84 308/QALY). pola-R-CHP was no longer cost-effective if its 5-year PFS was 66.1% or lower. One-way sensitivity analysis revealed that pola-R-CHP is cost-effective up to a cost of $276 312 at a WTP of $150 000. pola-R-CHP was the cost-effective strategy in 56.6% of the 10 000 Monte Carlo iterations at a WTP of $150 000. If the absolute benefit in PFS is maintained over time, pola-R-CHP is cost-effective compared with R-CHOP at a WTP of $150 000/QALY. However, its cost-effectiveness is highly dependent on its long-term outcomes and costs of chimeric antigen receptor T-cell therapy. Routine usage of pola-R-CHP would add significantly to health care expenditures. Price reductions or identification of subgroups that have maximal benefit would improve cost-effectiveness.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thiruvengadam SK, Saumoy M, Schneider Y, et al. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 2022. PMID: 35700381. doi:10.1182/blood.2022016624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。